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Antibiotic exposure exerts strong selective pressure and is an important modifiable risk factor for antibiotic
resistance. We aimed to identify the role of various antibiotics as risk factors for the isolation of extended-
spectrum--lactamase (ESBL)-producing Klebsiella spp. in hospitalized patients at a tertiary-care hospital. A
parallel multivariable model was created to compare two groups of cases with either nosocomially acquired
ESBL- or non-ESBL-producing Klebsiella spp. to a common control group of hospitalized patients (a case-
case-control design). Seventy-eight ESBL cases, 358 non-ESBL cases, and 444 controls were analyzed. Signif-
icant factors associated with the isolation of Klebsiella spp. were an age of >65 years, transfer from a health
care facility, an intensive care unit (ICU) stay, and the presence of a comorbid malignancy or lung, hepatic, or
renal disease. A propensity score was generated from the above, and our ability to discriminate between
Klebsiella cases and controls (area under the receiver-operating-characteristic [ROC] curve, 0.78) was good.
The ESBL phenotype was tightly linked with fluoroquinolone resistance (95% versus 18%, P < 0.001). Factors
associated with isolation of ESBL Klebsiella spp. in a multivariable analysis, adjusting for the propensity score,
included exposure to -lactam–-lactamase inhibitor combinations (odds ratio [OR], 10.17; 95% confidence
interval [CI], 1.19 to 86.92) and to fluoroquinolones (OR, 2.86; 95% CI, 1.37 to 5.97). Exposure to broad-
spectrum cephalosporins was statistically associated with ESBL Klebsiella spp. only among the subgroup of
patients not treated with fluoroquinolones. In our institution, where the ESBL-producing-Klebsiella phenotype
is coselected with fluoroquinolone resistance, fluoroquinolone and -lactam–-lactamase inhibitor combina-
tions, rather than cephalosporins, are the main risk factors for ESBL isolates. Formulary interventions to limit
the spread of ESBL-producing isolates should be tailored to each setting.
The emergence of nosocomially as well as community-
acquired extended-spectrum--lactamase (ESBL)-producing
Klebsiella spp. has increased sharply in recent years (5, 7, 42).
In the early 2000s, a high proportion of ESBL-producing
Gram-negative bacilli was reported, particularly from coun-
tries in South America, Asia, and the Mediterranean basin,
reaching 50% in many parts of the world (54). In the United
States, during 2003, 20.6% of K. pneumoniae isolates from
patients in the intensive care units (ICU) of hospitals partici-
pating in the National Nosocomial Infections Surveillance
(NNIS) System were not susceptible to broad-spectrum ceph-
alosporins, and the great majority of them were likely ESBL
producers (9, 51). This proportion of resistant isolates repre-
sented a 47% increase in the proportion of resistant isolates
compared to similar data collected between 1998 and 2002.
ESBL producers are often multidrug-resistant strains exhib-
iting coresistance to other classes of antibiotics, including tri-
methoprim-sulfamethoxazole, aminoglycosides, and the fluo-
roquinolones (12, 50). Thus, very few treatment options are
available for empirical as well as for definite therapy (28, 37).
Infections caused by ESBL producers have been associated
with severe adverse clinical outcomes, leading to increased
mortality, prolonged hospital stay, and increased costs (49).
These adverse outcomes have been related, at least in part, to
a delay in effective therapy (1, 20, 41, 53).
Various modes of ESBL dissemination, including clonal
spread, plasmid spread, and -lactamase gene transfer via in-
tegrons, have been described (10, 32). From the individual-
patient perspective, all of these events represent acquisition of
the resistant determinant from an extrinsic source. Both dis-
semination and mutational events are likely to occur under
antibiotic selection pressure (4, 18). Indeed, untoward emer-
gence of bacterial resistance by antibiotic agents, referred to as
“collateral damage,” is now being appreciated (34).
Several studies have examined the association between an-
tibiotic use and ESBL production either at the group level
(“ecological studies”) or at the individual level (“risk factor
analysis”). Most studies have implicated broad-spectrum ceph-
alosporins as the major class associated with ESBL production
(2, 23, 30, 31, 38, 43, 44), whereas results regarding the risk
associated with -lactam–-lactamase inhibitor combinations
vary (15, 19). In recent years, the use of fluoroquinolones has
increased dramatically in U.S. hospitals (33). This may have
affected the spread of ESBL-producing organisms. Moreover,
most of the previously published risk factor studies used a
case-control design with patients who have the resistant form
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of the organism versus those who have the susceptible form of
the organism. This may have created selection bias, which may
have generated distorted effect estimates of association be-
tween resistance and antibiotic utilization (14, 16, 17). Alter-
natively, the case-case-control study design contrasts two sep-
arate case-control analyses within a single study, which enables
more accurate identification of risk factors for antimicrobial-
resistant pathogens (21). Thus, for example, one is able to
identify variables specifically predictive of ESBL-producing
Klebsiella spp. without violating epidemiological principles of
control group selection (14). In this study, we aimed to study
the impact of antibiotic use on the isolation of ESBL-produc-
ing Klebsiella species isolates in an era of high fluoroquinolone
use, by using the case-case-control study design.
MATERIALS AND METHODS
Study design, populations, and definitions. A case-case-control study design
was used. Two concurrent retrospective analyses were performed on patients
admitted to the Beth Israel Deaconess Medical Center, a 640-bed tertiary-care
hospital in Boston, MA, from 1999 to 2001. Patients were eligible for inclusion
in this study if they were admitted to the hospital’s medical or surgical service. No
pediatric, obstetrics, gynecology, or psychiatry patients were included. Data were
extracted from the hospital’s computerized clinical, administrative, pharmacy,
and laboratory data repositories by using data management software (Microsoft
Access). The first group of cases was defined as patients from whom ESBL-
producing Klebsiella spp. were isolated. The second group of cases was defined as
patients from whom non-ESBL-producing Klebsiella spp. were isolated. Patients
with Klebsiella spp. isolated 48 h after hospitalization or from a nonclinical
surveillance culture (e.g., stool or nares) were excluded. To diminish the effect of
potential confounding due to infection control interventions, each group was
compared to a common control group of hospitalized patients without Klebsiella
infection (with a length of stay of at least 2 days) during the same study period.
Controls were randomly chosen by allocating a random number to all eligible
controls. Each patient was included as a subject only once, at the time of the
initial positive culture. Klebsiella species isolates were identified to the species
level and MICs determined using the Vitek 2 system (bioMe´rieux, Inc., Durham,
NC). ESBL production of Klebsiella spp. was confirmed by double disk diffusion
according to CLSI guidelines.
Risk factors. For all subjects, information on demographics, comorbidities,
and antibiotic exposures were obtained from the hospital’s computerized admin-
istrative, pharmacy, and laboratory databases. Variables analyzed as possible risk
factors included age, gender, transfer from another health care facility (hospital,
chronic-care facility), surgical procedure or intensive care unit stay prior to
isolation of the Klebsiella spp., and number of days at risk (days of hospitalization
prior to isolation of Klebsiella spp. for cases or days of hospitalization for con-
trols). Comorbidities were acquired from the International Classification of
Diseases diagnostic codes (ninth revision) (56). Antibiotics administered during
the hospitalization but prior to the isolation of a positive Klebsiella species
culture were documented and categorized by agent (penicillins, aminoglycosides,
fluoroquinolones, vancomycin, metronidazole, -lactam–-lactamase inhibitor
combinations, carbapenems, and narrow- and broad-spectrum cephalosporins).
All risk factors were analyzed as dichotomous variables, except for number of
days at risk, which remained a continuous variable.
Statistical analysis. Parallel case-control analyses of ESBL-producing Kleb-
siella species cases versus controls and non-ESBL-producing Klebsiella species
cases versus controls were performed to evaluate the relationship between each
variable and the likelihood of isolating the organism. Risk factors established
prior to the nosocomial isolation of Klebsiella spp. were examined by univariate
analysis. All analyses were then adjusted for numbers of days the patients were
at risk by including number of days at risk as a covariate in all analyses. Odds
ratios (OR) and 95% confidence intervals (CI) were calculated for binomial
variables. Individual risk factors were identified using logistic-regression models
adjusted for numbers of days at risk. To assess the impact of exposure to
individual antimicrobial agents on the isolation of Klebsiella spp. and limit
confounding by nonantimicrobial risk factors, a propensity score was con-
structed using nonantimicrobial variables. In essence, the propensity score
represents a composite risk incorporating the nonantimicrobial covariates for
each subject and was used in subsequent models to adjust for potential
confounding (8, 24, 48).
Those factors preliminarily associated with Klebsiella spp. by the logistic-
regression models adjusted for number of days at risk (P  0.10) were included
by stepwise selection in a multivariable logistic-regression model (where 0.05 was
set as the limit for the acceptance or removal of new terms) to determine the
relative contribution of each variable to the final propensity score. Next, with
ESBL-producing and non-ESBL-producing Klebsiella spp. considered separately
as outcomes in two different models, individual antibiotics were analyzed using
logistic-regression models adjusted for nonantibiotic risk factors using the pro-
pensity score and for number of days at risk. Since several antibiotic agents are
often used to treat an individual patient (either concomitantly or sequentially),
antibiotics significantly associated with Klebsiella spp. (P  0.05) were then
included in multivariable logistic-regression models adjusted for the propensity
score, again with either ESBL- or non-ESBL-producing Klebsiella spp. as the
outcome.
Analyses were performed using STATA version 7.0 (STATA Corp., College
Station, TX) and SAS, version 8.1 (SAS Institute, Cary, NC). The study was
approved by the Committee on Clinical Investigation of Beth Israel Deaconess
Medical Center.
RESULTS
Patient characteristics. During the 3 years studied, 426 Kleb-
siella species cases (78 ESBL- and 358 non-ESBL-producing
isolates) were enrolled. Of the Klebsiella species isolates, 343
were K. pneumoniae, 85 were K. oxytoca, 1 was K. ozaenae, and
7 were not identified to the species level. Four hundred forty-
four randomly selected patients without Klebsiella infection,
admitted to a medical or surgical service during the same time
period and hospitalized at least 2 days, were included as con-
trols. The median age of cases with Klebsiella infection was 69
years, the median number of days at risk was 8 (mean, 13.9),
and 40.1% of the patients were male. Of Klebsiella species
cultures, 8.5% were from blood, 46.1% from urine, and
31.7% from respiratory samples. The majority of ESBL-
producing Klebsiella species isolates were from respiratory
samples (41.0%), whereas the majority of non-ESBL-produc-
ing Klebsiella spp. were from urine (49.2%). The ESBL phe-
notype was tightly linked with fluoroquinolone resistance; 95%
of the ESBL-producing Klebsiella spp. were also fluoroquin-
olone resistant versus only 18% of the non-ESBL-producing
isolates (P  0.001). The median age of controls was 62 years,
the median number of days at risk was 5 days (mean, 7.1 days),
and 42.3% of the controls were male. The distribution of pa-
tients’ demographics, clinical characteristics, and antibiotic co-
variates by cases and controls is presented in Table 1.
Using nonantibiotic variables, we constructed a propensity
score predicting a patient’s probability of being infected with
Klebsiella spp. Of the nonantibiotic covariates ultimately in-
cluded in the propensity-adjusted analysis, an age of65 years,
transfer from another health care facility, prior ICU stay, prior
surgery, concomitant respiratory, renal, or hepatic disease, and
concurrent malignancy were all associated (P  0.05) with
isolation of Klebsiella spp. (Table 2). The variable number of
days at risk was included along with these covariates to gener-
ate the propensity score. Prior cardiovascular disease was re-
moved from the final propensity-adjusted model, as it did not
alter the effect estimates or improve the discriminatory power
of the model whether or not it was included. The propensity
score was generated from the above-named covariates with a
good ability to discriminate between Klebsiella cases (both non-
ESBL and ESBL producers) and controls (area under the
receiver-operating-characteristic [ROC] curve, 0.78) (Fig. 1).
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Propensity score-adjusted analysis of antibiotic risk factors.
The results of propensity score-adjusted antibiotic risk factor
analysis for the isolation of ESBL- and non-ESBL-producing
Klebsiella spp. are presented in Table 3. Isolation of ESBL-
producing Klebsiella spp. was associated with prior use of -lac-
tam–-lactamase inhibitor combinations, penicillins, aminogly-
cosides, fluoroquinolones, and metronidazole. Of note, in this
analysis, use of neither narrow- nor broad-spectrum cephalo-
sporins was predictive of ESBL-producing Klebsiella species
isolation, although a trend toward association (P  0.07) was
detected between the use of broad-spectrum cephalosporins
and the isolation of ESBL-producing Klebsiella species. Biva-
riate analysis of non-ESBL-producing Klebsiella cases versus
controls identified both fluoroquinolones and broad-spectrum
cephalosporins as being protective against an outcome of iso-
lation of non-ESBL-producing Klebsiella spp.
Table 4 presents the results of the multivariable logistic-
regression analysis of antibiotic risk factors for the outcome of
ESBL-producing Klebsiella species isolation. When we ad-
justed for prediction variables, only exposure to -lactam–-
lactamase inhibitor combinations and exposure to fluoroquin-
olone antibiotics were found to be independently associated
(P  0.05) with isolation of ESBL-Klebsiella spp. Additionally,
we detected a significant effect modification between fluoro-
TABLE 1. Distribution of demographics, clinical characteristics, and antibiotic exposures of case and control groups
Variable
No. (%) of:
Cases
Controls (n  444)
ESBL (n  78) Non-ESBL (n  358)
Demographics
Age of 65 yra 39 (50.00) 210 (58.66) 205 (46.17)
Male 35 (44.87) 140 (39.11) 188 (42.34)
Transferred from health care facilitya 58 (74.36) 252 (70.39) 241 (54.28)
Surgerya 39 (50.00) 171 (47.77) 165 (37.16)
ICU staya 60 (76.92) 193 (53.91) 72 (16.22)
Comorbidities
Cardiovascular disease 50 (64.10) 257 (71.79) 254 (57.21)
Respiratory diseasea 53 (67.95) 149 (41.62) 94 (21.17)
Renal diseasea 20 (25.64) 58 (16.20) 25 (5.63)
Hepatic diseasea 12 (15.38) 49 (13.69) 30 (6.76)
Transplant 3 (3.85) 5 (1.40) 10 (2.25)
Malignancya 8 (10.26) 63 (17.60) 56 (12.61)
Diabetes mellitus 18 (23.08) 74 (20.67) 104 (23.42)
Antibiotic exposure
Broad-spectrum cephalosporins 34 (43.59) 50 (13.97) 38 (8.56)
Narrow-spectrum cephalosporins 12 (15.38) 69 (19.27) 88 (19.82)
Penicillins 38 (48.72) 79 (22.07) 58 (13.06)
-Lactam–-lactamase inhibitor combinations 21 (26.92) 28 (7.82) 7 (1.58)
Piperacillin 1 (1.28) 3 (0.84) 2 (0.45)
Fluoroquinolones 52 (66.67) 86 (24.02) 115 (25.90)
Aminoglycosides 21 (26.92) 36 (10.06) 24 (5.41)
Clindamycin 10 (12.82) 21 (5.87) 13 (2.93)
Metronidazole 45 (57.69) 86 (24.02) 75 (16.89)
Trimethoprim-sulfamethoxazole 6 (7.69) 11 (3.07) 22 (4.95)
Carbapenems 2 (2.56) 5 (1.40) 3 (0.68)
a Nonantibiotic covariates finally included in the propensity score model.
TABLE 2. Time-at-risk-adjusted odds of nonantibiotic covariates
for isolation of any Klebsiella species included in the propensity
score model
Variable OR 95% CI P
Age of 65 yr 1.73 1.30–2.31 0.001
Transfer from another
health care facility
2.21 1.22–4.01 0.009
Surgery 1.38 1.03–1.85 0.0001
ICU stay 11.74 6.35–21.69 0.0001
Respiratory disease 5.94 3.37–10.46 0.0001
Renal disease 4.63 2.25–9.54 0.0001
Hepatic disease 2.33 1.06–5.13 0.036
Malignancy 1.62 1.09–2.41 0.017
FIG. 1. Propensity score-generated ROC curve.
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quinolones and broad-spectrum cephalosporins; i.e., the effect
of broad-spectrum cephalosporins on the risk of isolation of
ESBL-Klebsiella spp. differed between patients treated with
fluoroquinolones and those who were not. Thus, a subanalysis
was run to examine the effect of broad-spectrum cephalospo-
rins on the isolation of ESBL-producing Klebsiella spp. after
stratification for fluoroquinolone use. In this analysis, broad-
spectrum cephalosporin use was found to be predictive of
isolation of ESBL-producing Klebsiella spp. among the sub-
group of 346 patients not exposed to fluoroquinolones (OR,
3.63; P  0.025) and not among the subgroup of 167 fluoro-
quinolone-exposed patients (OR, 1.09; P  0.45).
DISCUSSION
Antibiotic resistance is an increasing clinical problem world-
wide and a valid public health threat (42). ESBL-producing
Enterobacteriaceae are prototypic examples of this threat, as
these organisms are often multidrug resistant and only carbap-
enems are a proven effective therapy against them (37). Anti-
biotic pressure is a major determinant of the emergence and
dissemination of antibiotic-resistant organisms (4). Moreover,
it is among the few modifiable factors predisposing patients to
infections with resistant organisms. Since antibiotic agents and
classes may differ in their propensities to promote resistance
(34), great interest exists in understanding the complex inter-
action between antibiotic use and the emergence and spread of
resistance.
Data from ecological studies have been highly supportive of
the association between cephalosporin use (particularly broad-
spectrum cephalosporins) and ESBL resistance in Gram-neg-
ative bacilli (predominantly K. pneumoniae) (43). This associ-
ation has been best displayed by interventional studies aimed
at decreasing the use of cephalosporins, which were found to
be effective in reducing the incidence of ESBL-producing K.
pneumoniae (23, 26, 40, 44, 46). It has also been demonstrated
that replacing cephalosporins with antibiotics containing -lac-
tamase inhibitors may help to reduce the occurrence of ESBL-
producing organisms (26). While useful in providing cumula-
tive data regarding antimicrobial use and resistance, ecological
studies do not link individual exposure histories to individual
outcome events. Therefore, elucidating causal relationship be-
tween antibiotic exposure and resistance based solely on ag-
gregated data may yield distorted results, as has been demon-
strated previously for Gram-negative bacilli (13). Moreover,
most ecological studies regarding antibiotic resistance per-
formed in the past did not use appropriate methodology, as has
been discussed by the ORION group (52), and were subject to
publication bias. We do not dismiss the evidence provided by
previous ecological studies that the level of cephalosporins use
is directly associated with the incidence of ESBL-producing
Gram-negative bacilli. However, we think that these observa-
tions should be considered with caution.
The effect of antibiotic exposure on ESBL resistance has
also been studied by several individual patient-level risk factor
analyses, yielding diverse results. The use of ceftazidime (31),
broad-spectrum cephalosporins and aminoglycosides (2),
ciprofloxacin and/or trimethoprim-sulfamethoxazole (55),
and cephalosporins, fluoroquinolones, and penicillins (11)
was identified as a risk factor for isolation of ESBL-producing
K. pneumoniae in different case-control studies. It is likely that
differences in local epidemiology, e.g., nursing homes versus
acute-care hospitals versus a community setting, explain part of
the diversity of results. In addition, methodological differences,
e.g., the definition of case patients and the selection of control
groups, may lead to selection bias in some studies and contrib-
TABLE 3. Propensity score-adjusted antibiotic risk factors for the isolation of ESBL- and non-ESBL-producing
Klebsiella species from cases versus controls
Variable (antibiotic exposure)
Bivariate result for the following comparisona:
ESBL vs control Non-ESBL vs control
OR 95% CI P OR 95% CI P
Broad-spectrum cephalosporins 1.89 0.94–3.78 0.07 0.51 0.29–0.87 0.02
Narrow-spectrum cephalosporins 0.74 0.33–1.62 0.45 0.74 0.49–1.11 0.14
Penicillins 4.29 2.23–8.26 <0.01 1.24 0.80–1.91 0.33
-Lactam–-lactamase inhibitor combinations 13.48 4.35–41.74 <0.01 2.38 0.93–6.14 0.07
Piperacillin 2.94 0.20–44.13 0.44 1.33 0.17–10.66 0.79
Fluoroquinolones 2.52 1.37–4.64 0.01 0.37 0.25–0.56 <0.01
Aminoglycosides 5.34 2.16–13.18 <0.01 1.44 0.76–2.72 0.26
Clindamycin 2.30 0.75–7.03 0.15 1.64 0.73–3.69 0.23
Metronidazole 2.83 1.53–5.22 <0.01 0.80 0.53–1.20 0.28
Trimethoprim-sulfamethoxazole 1.00 0.32–3.20 1.00 0.44 0.19–1.04 0.06
Carbapenems 0.46 0.07–3.28 0.44 0.32 0.07–1.42 0.13
a Boldface indicates statistical significance.
TABLE 4. Multivariable model of antibiotic risk factors for
the isolation of ESBL-producing Klebsiella spp. after
adjustment for propensity score
Variable (antibiotic exposure)
Isolation of ESBL-producing
Klebsiella spp.
OR 95% CI Pa
Penicillins 1.50 0.65–3.52 0.33
-Lactam–-lactamase inhibitor
combinations
10.17 1.19–86.92 0.03
Fluoroquinolones 2.86 1.37–5.97 0.01
Aminoglycosides 2.76 0.98–7.77 0.06
Metronidazole 1.74 0.85–3.57 0.13
a Boldface indicates statistical significance.
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ute to the nonuniformity of the results, as has been discussed
in detail by D. L. Paterson (35).
In order to avoid selection bias and to allow us to control for
confounding elements, we used the case-case-control study
design and compared in parallel two groups of case patients
(i.e., those with ESBL- or non-ESBL-producing Klebsiella spp.)
to a common control group of hospitalized patients without
Klebsiella infection (21). This study design, as has been dis-
cussed previously, is considered to be an effective and more
accurate tool to identify risk factors for resistant organisms
than the standard case-control study design (35). To further
control for confounding, we created a propensity score, which
expressed well the individual composite risk of being a Kleb-
siella case (area under the ROC curve, 0.78), and included it in
the multivariate analysis examining the relation between anti-
biotic exposure and isolation of ESBL- and non-ESBL-produc-
ing Klebsiella spp. After adjustment for the nonantimicrobial
risk factors, the only antibiotics that were independently
associated with the isolation of ESBL-producing Klebsiella
spp. included -lactam–-lactamase inhibitor combinations
and fluoroquinolones. Of note, exposure to broad-spectrum
cephalosporins was associated with ESBL-producing Kleb-
siella spp. only among the subgroup of patients not treated
with fluoroquinolones.
The association between fluoroquinolone resistance and
ESBL-producing Escherichia coli and K. pneumoniae has been
explored in previous studies (29). It is estimated that, world-
wide, more than half of ESBL-producing E. coli and Klebsiella
species isolates may be fluoroquinolone resistant (33, 55).
Likewise, in a multicenter study of K. pneumoniae bacteremia,
60% of the ciprofloxacin-resistant isolates were also identified
as ESBL producers (39). Indeed, among our study population,
the ESBL phenotype was tightly linked with fluoroquinolone
resistance (95% of the ESBL-producing Klebsiella spp. were
also fluoroquinolone resistant versus only 18% of the non-
ESBL-producing isolates [P  0.001]).
Fluoroquinolone antimicrobials have a strong impact on the
gastrointestinal flora; typical changes include a strong suppres-
sion of the Gram-negative facultative bacteria of the lower
intestinal flora that is much more prominent and prolonged
than that of other antibacterials (25, 45). Prior fluoroquinolone
use indeed is a known risk factor for isolation of quinolone-
resistant Gram-negative bacteria (27, 29).
The two aforementioned factors, i.e., ESBL and quinolone
coresistance and the impact of fluoroquinolones on the gas-
trointestinal flora, provide a potential explanation for our find-
ings that exposure to fluoroquinolones acts as an independent
risk factor for isolation of ESBL-producing Klebsiella spp. but
that exposure to cephalosporins acts as an independent risk
factor only in the subgroup of patients not exposed to fluoro-
quinolones.
Another case–double-control study by Rodriguez-Bano et
al. identified the use of fluoroquinolones as well as oxy-
imino--lactams as an independent risk factor for blood-
stream infections caused by ESBL-producing E. coli (47).
Since most non-ESBL-producing Klebsiella isolates are sus-
ceptible to cephalosporins and fluoroquinolones, infection
during antibiotic treatment is unlikely with susceptible strains;
thus, these agents are protective toward the outcome of non-
ESBL-producing Klebsiella species isolation. Certainly, molec-
ular data and clonality, which could shed more light on the
mechanisms explaining the associations found, are missing.
The association between -lactam–-lactamase inhibitor
combinations and ESBL-producing Klebsiella isolation in the
present study is remarkable, particularly since in the multiva-
riable analysis the effect estimate associated with -lactam–-
lactamase inhibitor combinations was the greatest among all of
the agents studied. -Lactamase inhibitors currently in clinical
use (clavulanate, sulbactam, and tazobactam) are Ambler class
A enzyme inhibitors, yet ESBL-producing strains in most parts
of the world show high rates of resistance to -lactam–-
lactamase inhibitor combinations (3, 50). This is likely related
to cocarriage of OXA enzymes (which are not inhibited by the
Ambler class A enzyme inhibitors) on the ESBL plasmid,
hyperproduction of the ESBL enzyme, or coresidence of
non-ESBL enzymes, such as plasmid-encoded Ambler class
C -lactamases, potentially in combination with a porin muta-
tion or, much less frequently, in combination with an inhibitor
resistance mutation in the ESBL itself (e.g., the complex mu-
tant TEM -lactamases) (6, 36). Indeed, emergence of resis-
tance and treatment failure during -lactam–-lactamase in-
hibitor combination treatment has been reported (57). Studies
of the effects of these agents as risk factors for ESBL vary;
some have described them as protective (19) while others have
described them as a significant risk factor (15). This discrep-
ancy may be related to geographical changes in ESBLs and
cocarried resistance genes and differences in local usage pat-
terns of specific inhibitor combinations, as well as to differ-
ences in study designs and choice of control groups. During
this time period at the study institution, about half of the
ESBL-producing Klebsiella isolates were susceptible to pip-
eracillin-tazobactam, whereas none were susceptible to ampi-
cillin-sulbactam (amoxicillin-clavulanate was not routinely
tested). Due to data extraction limitations, we were not able to
differentiate between specific inhibitor combinations.
Our study has several limitations. First, it is a retrospective
study; thus, some of the data may be incompletely reported.
We do not believe that this is a major problem, as the data
included in the study are routinely recorded in the patient
chart. Second, categorization of prior antibiotic use was based
on drug classes rather than the specific agent. While agents
belonging to the same class may have different effects on re-
sistance (22), most studies assume a uniform class effect; there-
fore, comparison is possible. We suggest that future studies
should focus on this issue of within-class differences, obviously
necessitating much larger data sets. Third, the unequal sizes of
the two case groups result in reduced statistical power to detect
variables as significant risk factors for the ESBL cases com-
pared to the non-ESBL cases.
In conclusion, exposure to fluoroquinolones or to -lactam–
-lactamase inhibitor combinations during hospitalization is a
risk factor for ESBL-producing Klebsiella infections, while
broad-spectrum cephalosporins are predictive of isolation of
ESBL-producing Klebsiella spp. among hospitalized patients
not treated with fluoroquinolones. Knowledge of patients’
prior antimicrobial exposures may be helpful in selecting an
empirical treatment of nosocomial Klebsiella species infections.
Formulary interventions to limit the spread of ESBLs may
need to be tailored based on the local epidemiology and risk
factors.
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